ZUBEREITUNG VON BUPRENORPHIN

Patent europeic · EP4090662 · En vigur

Inscripziun en il register

Numer da publicaziun
EP4090662
Numer da la dumonda
EP21701689
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
14-01-2021
Publitgà
23-11-2022
Concedì
12-06-2024
La protecziun finescha il pli tard
13-01-2041
Proxima taxa annuala scadenta
31-01-2027
Classas IPC
C07D 489/02 (2006.01)
Prioritad
US 202062962335 P 17.01.2020
Dumonda PCT
PCT/EP2021/050692 14.01.2021
Publicaziun PCT
WO2021/144362 22.07.2021
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-02-2026

    Midada

    Published in Swissreg on 01.02.2026

  2. 23-04-2025

    Midada

    Published in Swissreg on 23.04.2025

  3. 01-02-2025

    Midada

    Published in Swissreg on 01.02.2025

  4. 29-01-2025

    Adressa dal represchentant midada

    Representative
    Cosmovici Intellectual Property Sàrl, Rue du Commerce 4, 1204 Genève → Cosmovici Intellectual Property, Rue de la Corraterie 5, 1204 Genève

    Published in Swissreg on 29.01.2025

  5. 02-07-2024

    Represchentant inscrit

    Representative
    Cosmovici Intellectual Property Sàrl, Rue du Commerce 4, 1204 Genève

    Published in Swissreg on 02.07.2024

  6. 12-06-2024

    Concedì

    Published in Swissreg on 12.06.2024

Partidas

Possessur

River Stone Biotech ApS

Symbion Science Park Fruebjergvej 3, 2100 Copenhagen, DK

Represchentant

Cosmovici Intellectual Property

Rue de la Corraterie 5, 1204 Genève

Inventur

SANTELLA, Marco

2100 Copenhagen, DK

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.